BACKGROUND AND OBJECTIVES: Light chain (AL) and secondary (AA) amyloidosis usually present as a systemic disease frequently involving the kidney and leading to ESRD. Data regarding patients with AA or AL amyloidosis undergoing dialysis remain scarce. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We retrospectively studied patients with AA or AL amyloidosis who started dialysis in five French centers between January 1, 1995 and December 31, 2005. RESULTS: We identified 19 patients with AL and 20 patients with AA amyloidosis undergoing dialysis. Patients with AL amyloidosis had shorter time from diagnosis to dialysis (25.2 versus 69.3 mo, P < 0.05) and more extrarenal amyloidosis, especially cardiac (63.2 versus 5%, P < 0.0001). Mean duration of follow-up was 37.4 and 31.8 mo for patients with AL and AA amyloidosis, respectively. Fifteen patients (78.9%) with AL and three patients (15%) with AA amyloidosis died on dialysis. Median survival was shorter in patients with AL (26 mo) than AA amyloidosis [not definable (ND)] (P < 0.02). Sepsis and cardiac deaths were the main causes of mortality. Prognosis factors for death at 1 yr were AL type (P < 0.01), cardiac amyloidosis [odds ratio (OR) = 18, P < 0.01], heart failure (OR = 8, P < 0.04), and shorter time from diagnosis to dialysis (6.1 versus 56 mo, P < 0.03). Multivariate analysis indicated that AL type (P = 0.02), but not cardiac amyloidosis was independently associated with global mortality. CONCLUSIONS: Survival of patients with amyloidosis undergoing dialysis, especially AL type, is probably better than previously reported. However, mortality is higher in AL than AA type, especially in the setting of cardiac involvement.
BACKGROUND AND OBJECTIVES: Light chain (AL) and secondary (AA) amyloidosis usually present as a systemic disease frequently involving the kidney and leading to ESRD. Data regarding patients with AA or AL amyloidosis undergoing dialysis remain scarce. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We retrospectively studied patients with AA or AL amyloidosis who started dialysis in five French centers between January 1, 1995 and December 31, 2005. RESULTS: We identified 19 patients with AL and 20 patients with AA amyloidosis undergoing dialysis. Patients with AL amyloidosis had shorter time from diagnosis to dialysis (25.2 versus 69.3 mo, P < 0.05) and more extrarenal amyloidosis, especially cardiac (63.2 versus 5%, P < 0.0001). Mean duration of follow-up was 37.4 and 31.8 mo for patients with AL and AA amyloidosis, respectively. Fifteen patients (78.9%) with AL and three patients (15%) with AA amyloidosis died on dialysis. Median survival was shorter in patients with AL (26 mo) than AA amyloidosis [not definable (ND)] (P < 0.02). Sepsis and cardiac deaths were the main causes of mortality. Prognosis factors for death at 1 yr were AL type (P < 0.01), cardiac amyloidosis [odds ratio (OR) = 18, P < 0.01], heart failure (OR = 8, P < 0.04), and shorter time from diagnosis to dialysis (6.1 versus 56 mo, P < 0.03). Multivariate analysis indicated that AL type (P = 0.02), but not cardiac amyloidosis was independently associated with global mortality. CONCLUSIONS: Survival of patients with amyloidosis undergoing dialysis, especially AL type, is probably better than previously reported. However, mortality is higher in AL than AA type, especially in the setting of cardiac involvement.
Authors: Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright Journal: Ann Intern Med Date: 2004-01-20 Impact factor: 25.391
Authors: Angela Dispenzieri; Robert A Kyle; Morie A Gertz; Terry M Therneau; Wayne L Miller; Krishnaswamy Chandrasekaran; Joseph P McConnell; Mary F Burritt; Allan S Jaffe Journal: Lancet Date: 2003-05-24 Impact factor: 79.321
Authors: K Ylinen; C Grönhagen-Riska; E Honkanen; A Ekstrand; K Metsärinne; B Kuhlbäck Journal: Nephrol Dial Transplant Date: 1992 Impact factor: 5.992
Authors: G Moroni; G Banfi; A Montoli; A Bucci; T Bertani; M Ravelli; C Pozzi; M Leonelli; A Lupo; A Volpi Journal: Clin Nephrol Date: 1992-08 Impact factor: 0.975
Authors: Marie C Iliou; Christine Fumeron; Marie O Benoit; Philippe Tuppin; Victorio Menoyo Calonge; Nicole Moatti; Claude Buisson; Christian Jacquot Journal: Am J Kidney Dis Date: 2003-09 Impact factor: 8.860
Authors: Jean Michel Saad; Ahmed Ibrahim Ahmed; Dixitha Anugula; Yushui Han; Moath Said Alfawara; Mouaz H Al-Mallah Journal: Methodist Debakey Cardiovasc J Date: 2022-03-14
Authors: Cihan Heybeli; Andrew Bentall; Jiqiu Wen; Mariam Priya Alexander; Francis K Buadi; Fernando G Cosio; Patrick G Dean; Angela Dispenzieri; David Dingli; Mireille El Ters; Morie A Gertz; Amer Hatem; Prashant Kapoor; Hasan Khamash; Taxiarchis Kourelis; Shaji Kumar; Elizabeth C Lorenz; Martin Mai; Eli Muchtar; David L Murray; Mikel Prieto; Carrie A Schinstock; Mark D Stegall; Rahma Warsame; Nelson Leung Journal: Kidney Int Date: 2020-07-23 Impact factor: 10.612
Authors: Roel A van der Heijden; Johan Bijzet; Wouter C Meijers; Gopala K Yakala; Robert Kleemann; Tri Q Nguyen; Rudolf A de Boer; Casper G Schalkwijk; Bouke P C Hazenberg; Uwe J F Tietge; Peter Heeringa Journal: Sci Rep Date: 2015-11-13 Impact factor: 4.379